Trial Profile

A retrospective study Cefiderocol for Treatment of Patients with Gram-Negative Respiratory Infections in US hospitals

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 30 Nov 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cefiderocol (Primary)
Indications Acinetobacter infections; Gram-negative infections; Klebsiella infections; Pseudomonal infections
Focus Adverse reactions

Most Recent Events

30 Nov 2022 New trial record
19 Oct 2022 Results (n=113) presented at the CHEST Annual Meeting 2022 by Annual Meeting of the American College of Chest Physicians

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com